Blood Cancers Today’s Post

💫ONCOnews💫 🌟 Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study 👉 Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma 🔗 https://buff.ly/3Q0aMGr #OncEd #ONCOnews #OncoAlert

In this study of children with Hodgkin lymphoma treated in 4 consecutive RCTs 2002-22, the 30-year risk of late cardiac complications is estimated to decrease from 10% to 6%, with cardioprotective chemo and lower radiation dose to heart. https://ja.ma/3O8Hh4e

✅Accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma. The recommended lisocabtagene maraleucel dose is 90 to 110 × 106 CAR-positive viable T cells with a 1:1 ratio of CD4 & CD8 components. READ➡️https://lnkd.in/eAFyJJ5x

B-cell maturation antigen expression & clinical features of plasmablastic lymphoma: - 17/18 patients w BCMA expression on IHC (94%) - Median 75% of cells were BCMA+ - 61% intermed-strong BCMA staining https://lnkd.in/d64hwtqG #lymsm #lymphoma #mmsm #plasmablastic

The Smart Stop abstract examines the combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib in patients with newly diagnosed diffuse large B-cell lymphoma. Dr. Jason Westin discusses in this MEDtalk if targeted therapy can reduce or even eliminate the need for chemotherapy in these patients. Initial findings show a 63% complete response rate and a 100% overall response rate after four cycles of treatment. See all available ASH content here: https://lnkd.in/ewFP2hPn #ASH23 #Lymphoma

This study found that diffuse large B cell lymphoma (DLBCL) resistance to combine therapy rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP) linked to single nucleotide polymorphisms (SNPs) rs1883112 and rs1800871. These two SNPs can also be used as predictor for prognosis, since the study linked them to shortened progression free survival and overall survival. https://lnkd.in/g3uJVhuh

ASH 2023: Jelena Jelicic presented a study at the ASH meeting in San Diego on prognostic models for diffuse large B-cell lymphoma in patients under 70. The study aimed to evaluate the utility of different prognostic models, specifically comparing the traditional International Prognostic Index (IPI) with the more recent NCCN-IPI. The findings suggest that NCCN-IPI better discriminates between risk categories and could potentially include more patients in clinical trials. See all available ASH content here: https://lnkd.in/ewFP2hPn #ASH23 #Lymphoma 

Circulating angioimmunoblastic T-cell lymphoma cells https://lnkd.in/epvi2x57

Small Bowel Lymphoma: Facts From "CT of Lymphoma: Involvement of the GI Tract - Part 1" View the full lecture here: https://lnkd.in/gKzpp8cz

💫 ECHO Phase III trial 💫 🌟 CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in the ECHO Phase III trial 👉 First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting 🔗 https://buff.ly/3UnGBdK #OncEd #ONCOnews #OncoAlert